抗肽抗体、抗SNRK抗体和抗HUWE1抗体作为类风湿关节炎患者托法替布治疗良好反应的潜在预测因子
研究纳入106例接受24周托法替布治疗的类风湿关节炎患者,发现阶段12例行噬菌体免疫沉淀测序,验证阶段94例行酶联免疫吸附试验。抗SNRK抗体预测良好反应的AUC为0.823,抗HUWE1抗体AUC为0.740,抗SNRK抗体是多变量分析中良好治疗反应的显著预测因子。
要点
- 抗SNRK抗体预测良好反应的最佳截断值为0.381,AUC 0.823,特异性80.6%,敏感性78.1%。
- 抗HUWE1抗体预测良好反应的最佳截断值为0.362,AUC 0.740,特异性74.2%,敏感性62.5%。
- 抗SNRK和抗HUWE1抗体水平与caspase-1和IL-18水平呈正相关(均P<0.05)。
核心结论
- 研究识别出抗SNRK和抗HUWE1两种肽抗体,可作为类风湿关节炎患者托法替布治疗良好反应的治疗前预测因子。
研究设计与样本
- 研究纳入106例接受24周托法替布治疗的类风湿关节炎患者,其中发现阶段12例行噬菌体免疫沉淀测序分析,验证阶段94例行酶联免疫吸附试验验证。
- 疾病活动度采用28关节疾病活动度评分-红细胞沉降率评估,治疗反应采用EULAR反应标准评估。
- 血浆caspase-1和IL-18水平采用酶联免疫吸附试验测定。
主要发现
- 噬菌体免疫沉淀测序分析识别出抗SNRK(蔗糖非发酵相关激酶)和抗HUWE1(泛素E3连接酶)抗体作为区分良好反应者与非良好反应者的肽生物标志物。
- 在另一队列行酶联免疫吸附试验验证,抗SNRK抗体预测良好反应的最佳截断值为0.381,AUC 0.823,特异性80.6%,敏感性78.1%(P = 3.01E-07)。
- 抗HUWE1抗体预测良好反应的最佳截断值为0.362,AUC 0.740,特异性74.2%,敏感性62.5%(P < 0.001)。
- 血浆抗SNRK和抗HUWE1抗体水平与caspase-1和IL-18水平呈正相关(均P < 0.05)。
- 多变量logistic回归分析显示抗SNRK抗体是良好治疗反应的显著预测因子。
关键数值与推荐
- 抗SNRK抗体预测良好反应的最佳截断值为0.381,AUC 0.823,特异性80.6%,敏感性78.1%(P = 3.01E-07)。
- 抗HUWE1抗体预测良好反应的最佳截断值为0.362,AUC 0.740,特异性74.2%,敏感性62.5%(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To maximize the cost-effectiveness of tofacitinib, one of the Janus kinase inhibitors, there is an unmet need to identify predictors of therapeutic response. Utilizing phage immunoprecipitation sequencing (PhIP-Seq), we aim to identify peptide biomarkers for predicting good response to tofacitinib in rheumatoid arthritis (RA) patients. METHODS: We enrolled 106 patients who had received 24-week tofacitinib therapy, including 12 patients undergoing PhIP-Seq analysis in the discovery stage and 94 patients validated with enzyme-linked immunosorbent assay (ELISA) in the replication stage. Disease activity was assessed using the 28-joint disease activity score-erythrocyte sedimentation rate, and therapeutic response was evaluated using EULAR response criteria. Plasma levels of caspase-1 and IL-18 were determined using ELISA. RESULTS: PhIP-Seq analysis identified antibodies to sucrose non-fermenting-related kinase (SNRK) and HUWE1 (ubiquitin E3 ligase) as peptide biomarkers for discriminating good responders from the non-good responders. Using ELISA for validation on another cohort, an optimal cut-off value of anti-SNRK antibody for predicting good response was 0.381, with AUC 0.823, specificity 80.6% and sensitivity 78.1% (P = 3.01E-07), and anti-HUWE1 antibody at 0.362, with AUC 0.740, specificity 74.2% and sensitivity 62.5% (P < 0.001). Plasma levels of anti-SNRK and anti-HUWE1 antibodies were positively correlated with levels of caspase-1 and IL-18 (both P < 0.05). Multivariate logistic regression analysis revealed anti-SNRK antibody as a significant predictor of good therapeutic response. After tofacitinib therapy, anti-SNRK antibody levels significantly declined in good responders, but not in non-good responders. CONCLUSION: We identify two peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as pretreatment predictors of good therapeutic response to tofacitinib in RA patients.
引用
- Chen PK, Chen YM, Chen JJW, et al. Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2025. PMID: 39447044. doi:10.1093/rheumatology/keae595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。